236 related articles for article (PubMed ID: 19450643)
1. Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3.
Webb RP; Smith TJ; Wright P; Brown J; Smith LA
Vaccine; 2009 Jul; 27(33):4490-7. PubMed ID: 19450643
[TBL] [Abstract][Full Text] [Related]
2. Recombinant Botulinum Neurotoxin Hc Subunit (BoNT Hc) and Catalytically Inactive Clostridium botulinum Holoproteins (ciBoNT HPs) as Vaccine Candidates for the Prevention of Botulism.
Webb RP; Smith TJ; Smith LA; Wright PM; Guernieri RL; Brown JL; Skerry JC
Toxins (Basel); 2017 Sep; 9(9):. PubMed ID: 28869522
[TBL] [Abstract][Full Text] [Related]
3. The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate.
Yu YZ; Li N; Zhu HQ; Wang RL; Du Y; Wang S; Yu WY; Sun ZW
Vaccine; 2009 May; 27(21):2816-22. PubMed ID: 19428892
[TBL] [Abstract][Full Text] [Related]
4. Protection with a recombinant Hc of Clostridium Botulinum neurotoxin serotype A from Escherichia coli as an effective subunit vaccine.
Yu YZ; Sun ZW; Li N; Wang S; Wang RL; Yu WY
Immunopharmacol Immunotoxicol; 2009 Jun; 31(2):261-6. PubMed ID: 18932057
[TBL] [Abstract][Full Text] [Related]
5. Enhancing toxin-based vaccines against botulism.
Przedpelski A; Tepp WH; Zuverink M; Johnson EA; Pellet S; Barbieri JT
Vaccine; 2018 Feb; 36(6):827-832. PubMed ID: 29307477
[TBL] [Abstract][Full Text] [Related]
6. Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins.
Webb RP; Smith TJ; Wright PM; Montgomery VA; Meagher MM; Smith LA
Vaccine; 2007 May; 25(21):4273-82. PubMed ID: 17395341
[TBL] [Abstract][Full Text] [Related]
7. Subunit vaccine efficacy against Botulinum neurotoxin subtypes.
Henkel JS; Tepp WH; Przedpelski A; Fritz RB; Johnson EA; Barbieri JT
Vaccine; 2011 Oct; 29(44):7688-95. PubMed ID: 21839134
[TBL] [Abstract][Full Text] [Related]
8. Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris.
Byrne MP; Titball RW; Holley J; Smith LA
Protein Expr Purif; 2000 Apr; 18(3):327-37. PubMed ID: 10733887
[TBL] [Abstract][Full Text] [Related]
9. Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A.
Yu YZ; Zhang SM; Sun ZW; Wang S; Yu WY
Vaccine; 2007 Dec; 25(52):8843-50. PubMed ID: 18022294
[TBL] [Abstract][Full Text] [Related]
10. Botulism and vaccines for its prevention.
Smith LA
Vaccine; 2009 Nov; 27 Suppl 4():D33-9. PubMed ID: 19837283
[TBL] [Abstract][Full Text] [Related]
11. Mapping of the antibody and T cell recognition profiles of the HN domain (residues 449-859) of the heavy chain of botulinum neurotoxin A in two high-responder mouse strains.
Dolimbek GS; Dolimbek BZ; Aoki KR; Atassi MZ
Immunol Invest; 2005; 34(2):119-42. PubMed ID: 15921155
[TBL] [Abstract][Full Text] [Related]
12. Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F.
Yu YZ; Zhang SM; Ma Y; Zhu HQ; Wang WB; Du Y; Zhou XW; Wang RL; Wang S; Yu WY; Huang PT; Sun ZW
Clin Immunol; 2010 Nov; 137(2):271-80. PubMed ID: 20696619
[TBL] [Abstract][Full Text] [Related]
13. Vaccines against botulism.
Karalewitz AP; Barbieri JT
Curr Opin Microbiol; 2012 Jun; 15(3):317-24. PubMed ID: 22694934
[TBL] [Abstract][Full Text] [Related]
14. A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4.
Arndt JW; Jacobson MJ; Abola EE; Forsyth CM; Tepp WH; Marks JD; Johnson EA; Stevens RC
J Mol Biol; 2006 Sep; 362(4):733-42. PubMed ID: 16938310
[TBL] [Abstract][Full Text] [Related]
15. Botulinum neurotoxin neutralizing activity of immune globulin (IG) purified from clinical volunteers vaccinated with recombinant botulinum vaccine (rBV A/B).
Shearer JD; Vassar ML; Swiderski W; Metcalfe K; Niemuth N; Henderson I
Vaccine; 2010 Oct; 28(45):7313-8. PubMed ID: 20816903
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine.
Yu YZ; Li N; Wang RL; Zhu HQ; Wang S; Yu WY; Sun ZW
Clin Vaccine Immunol; 2008 Dec; 15(12):1819-23. PubMed ID: 18845829
[TBL] [Abstract][Full Text] [Related]
17. Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice.
Lee JS; Groebner JL; Hadjipanayis AG; Negley DL; Schmaljohn AL; Welkos SL; Smith LA; Smith JF
Vaccine; 2006 Nov; 24(47-48):6886-92. PubMed ID: 16828936
[TBL] [Abstract][Full Text] [Related]
18. High-level expression, purification, and characterization of recombinant type A botulinum neurotoxin light chain.
Li L; Singh BR
Protein Expr Purif; 1999 Dec; 17(3):339-44. PubMed ID: 10600450
[TBL] [Abstract][Full Text] [Related]
19. Easy expression of the C-terminal heavy chain domain of botulinum neurotoxin serotype A as a vaccine candidate using a bi-cistronic baculovirus system.
Villaflores OB; Hsei CM; Teng CY; Chen YJ; Wey JJ; Tsui PY; Shyu RH; Tung KL; Yeh JM; Chiao DJ; Wu TY
J Virol Methods; 2013 Apr; 189(1):58-64. PubMed ID: 23313783
[TBL] [Abstract][Full Text] [Related]
20. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A.
Dolimbek BZ; Aoki KR; Steward LE; Jankovic J; Atassi MZ
Mol Immunol; 2007 Feb; 44(5):1029-41. PubMed ID: 16647121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
